Showing 2301-2310 of 4063 results for "".
- Neurophth Announces IND Approval in China for Leber Hereditary Optic Neuropathy Gene Therapyhttps://modernod.com/news/neurophth-announces-ind-approval-in-china-for-leber-hereditary-optic-neuropathy-gene-therapy/2479055/Neurophth Biotechnology announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application of NR082 (recombinant adeno-associated virus serotype 2 carrying ND4 gene; rAAV2-ND
- Pfizer, Moderna COVID-19 Vaccines Show High Efficacy in First US Real-World Studyhttps://modernod.com/news/pfizer-moderna-covid-19-vaccines-show-high-efficacy-in-first-us-real-world-study/2479028/New data released Monday from a US Centers for Disease Control and Prevention (CDC) study of vaccinated health care workers show that mRNA-based coronavirus vaccines by Pfizer and Moderna were 80% effective at preventing infections after one dose, with efficacy climbing to 90% 2 weeks after the s
- Neurolens Announces the Launch of the nMD2 Measurement Devicehttps://modernod.com/news/neurolens-announces-the-launch-of-the-nmd2-measurement-device/2479022/Neurolens has announced the launch of the neurolens Measurement Device, Gen 2 (nMD2), an objective and repeatable way to measure binocular vision, or more specifically, eye alignment. Employing over 10,000 data points per patient, the eye tracking system can identify eye misalignment as small as
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- New Open Access Ophthalmology Journal Now Livehttps://modernod.com/news/new-open-access-ophthalmology-journal-now-live/2478998/Ophthalmology Science—the American Academy of Ophthalmology’s first open access journal—is now live and accepting submissions. Ophthalmology Science is an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our
- Pfizer, BioNTech’s COVID-19 Vaccine Neutralizes Brazil Variant in Lab Studyhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-neutralizes-brazil-variant-in-lab-study/2478953/According to laboratory study findings published Monday in the NEJM, Pfizer and BioNTech’s mRNA-based COVID-19 vaccine BNT162b2 was able to neutralize the P.1 variant of SARS-CoV-2 that first surfaced in Brazil. The news follows a report late last week that suggested AstraZeneca’s cor
- FDA Accepts Oyster Point’s Filing of NDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-oyster-points-filing-new-drug-application-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478928/Oyster Point Pharma announced that the FDA has accepted its new drug application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act (PDUFA) target action date for OC-01 (varenicline) nasal spray is October 17, 2
- Bio-Tissue Receives FDA Clearance to Proceed with Clinical Study Using Investigational New Drug TTBT01https://modernod.com/news/bio-tissue-receives-fda-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-ttbt01/2478924/Bio-Tissue announced that its parent company TissueTech had received clearance from the FDA to proceed with a phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) investigational new drug (IND) TTBT01. This clearance represents another milest